iCo Therapeutics Updates
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company is advancing an oral delivery program, beginning with Amphoterincin B, utilizing a known anti-fungal drug to treat life-threatening infectious diseases and treat latent HIV reservoirs. iCo has a partnership with Immune Pharmaceuticals for iCo-008 which is in clinical studies for bullous pemphigoid and ulcerative colitis, while maintaining ophthalmic rights. iCo-007 is a C-Raf inhibitor asset, not currently in development. iCo trades on the TSX Venture Exchange under the symbol “ICO” and the OTCQX under the symbol “ICOTF”.